$KRYS

Krystal Biotech (NASDAQ:KRYS) director Dino Rossi sells $8.2m shares

Krystal Biotech director Dino A. Rossi sold about 25,000 shares for roughly $8.23m on Aug. 14, 2026, per an SEC Form 4, at weighted average prices of $325.60 to $333.23. He also gifted 3,691 shares to a donor-advised fund. Krystal Biotech reported Q2 diluted EPS of $1.79 (vs $1.70 est.) and revenue of $119.2m (vs $122.3m est.).

Original reporting
Published Aug 14, 2026, 11:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 15, 2026, 2:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$KRYS
Neutral
medium confidence
Mentioned
$KRYS
Relevance
4/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$KRYSNeutralLow
01

Why it matters

Insider selling can be a sentiment headwind, but without new guidance, financing, or regulatory/clinical catalysts, the trading signal is likely secondary to the company’s operating updates.

02

Market read

A director’s multi-million-dollar share sale is newly disclosed, but the article does not add a new fundamental catalyst beyond referencing recent earnings.

03

What to watch

The article also mentions a quarterly EPS beat but revenue miss; traders may weigh that more than the insider sale when forming near-term views.

Relevance 4/10Novelty 5/10Timing: SEC Form 4 insider sale reported for Aug. 14, 2026.

Background

The piece centers on an SEC Form 4 by Krystal Biotech director Dino Rossi, alongside a brief recap of the company’s recent Q2 results.

Company-level read

Ticker impact

$KRYSNeutralMedium confidence
Context

Krystal Biotech director Dino Rossi sold about $8.23m of KRYS shares on Aug. 14, per an SEC Form 4, with sale prices $325.60 to $333.23.

Expected impact

Near-term sentiment could soften, but magnitude is likely limited without accompanying guidance, financing, or operational news.

Evidence & confidence

The article’s primary new fact is the director’s sale and a small charitable gift; it does not introduce new company fundamentals beyond referencing already-reported quarterly results.

Market effects

No clear sector read-through beyond routine insider activity in biotech.

None indicated.

None indicated.

Counterpoint

Director selling can be planned diversification or tax-related, so it may not signal deteriorating fundamentals.

Key entities

  • Krystal Biotech, Inc.

    NASDAQ-listed biotech whose director filed an SEC Form 4 reporting share sales and a charitable gift on Aug. 14, 2026.

  • Dino A. Rossi

    Director at Krystal Biotech who sold about 25,000 shares and made a charitable gift of 3,691 shares on Aug. 14, 2026.

Related articles

$KRYSMed

Why is Krystal Biotech stock sliding today?

Krystal Biotech (KRYS) shares fell about 6% in pre-open after it reported Q2 2026 results. The company posted $119.2M in global VYJUVEK net revenue, up 24% year over year but below analyst consensus near $126M. Gross margin was 95% and prescribers rose above 640, but the revenue miss drove selling.

$KRYSMed

Krystal Biotech, Inc. (KRYS): Results of Operations and Financial Condition

Krystal Biotech, Inc. (KRYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26-ex991xpressrelease.htm EX-99.1 Document Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results $119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launch

$AVEXLowAI 8/10

AVEX Shareholder Alert: October 20, 2026 Lead Plaintiff Deadline in AEVEX Corp. Securities Class Action - Contact Levi & Korsinsky

AEVEX Corp. (NYSE: AVEX) faces a securities class action lawsuit alleging its Board Chairman Brian Raduenz and others concealed a pre-arranged plan to waive a 180-day lock-up period for shareholders. The lawsuit claims misstatements in IPO documents led to a $900 million market value loss for AVEX shareholders in June 2026. The lead plaintiff deadline is October 20, 2026, according to Levi & Korsinsky, LLP.